Alerts will be sent to your verified email
Verify EmailJBCHEPHARM
JB Chem & Pharma
|
Pfizer
|
Astrazeneca Pharma I
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
19.0 . | n/a | n/a |
Number of ANDA's Approved By USFDA
|
17.0 . | n/a | n/a |
Domestic Sales Growth - YoY
|
10.1 % | 8.7 % | 18.6 % |
R&D as a % of Total Sales
|
1.16 % | n/a | 0.0 |
Financials
|
|||
5 yr Average ROE
|
19.44 % | 18.39 % | 18.37 % |
5yr average Equity Multiplier
|
1.5 | 1.28 | 1.94 |
5yr Average Asset Turnover Ratio
|
0.79 | 0.6 | 0.94 |
5yr Avg Net Profit Margin
|
16.41 % | 24.04 % | 10.03 % |
Price to Book
|
7.88 | 6.38 | 34.16 |
P/E
|
41.0 | 35.06 | 227.33 |
5yr Avg Cash Conversion Cycle
|
19.31 Days | -2.02 Days | -36.14 Days |
Inventory Days
|
51.72 Days | 49.44 Days | 64.11 Days |
Days Receivable
|
63.93 Days | 26.74 Days | 36.53 Days |
Days Payable
|
85.63 Days | 81.1 Days | 208.62 Days |
5yr Average Interest Coverage Ratio
|
65.09 | 170.95 | 140.96 |
5yr Avg ROCE
|
23.24 % | 23.56 % | 23.99 % |
5yr Avg Operating Profit Margin
|
23.72 % | 30.56 % | 14.51 % |
5 yr average Debt to Equity
|
0.08 | 0.0 | 0.0 |
5yr CAGR Net Profit
|
15.23 % | 65.36 % | 17.47 % |
5yr Average Return on Assets
|
13.06 % | 14.39 % | 9.52 % |
Shareholdings
|
|||
Promoter Holding
|
47.84 % | 63.92 % | 75.0 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-6.16 % | 0.0 | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
1.99 % | 3.65 % | 3.46 % |
JB Chem & Pharma
|
Pfizer
|
Astrazeneca Pharma I
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|